Site is Being Upgraded

Diabetes

December 17, 2018

A probiotic way to say no to Diabetes: Probiotic MIYAIRI 588-based therapy for diabetes (TIDM): Probiotic Clostridium butyricum MIYAIRI 588 (CBM588) increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene, 17/December/2018, 11.58 pm

Introduction: What they say A study from the Comprehensive Diabetes Center and Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Alabama at Birmingham, […]
December 16, 2018

A Probiotic way to say no to Diabetes: Probiotic VSL#3-based therapy for diabetes (TIDM): Probiotic VSL#3 increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene, 17/December/2018, 12.02 am

Introduction: What they say A study from the Comprehensive Diabetes Center and Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Alabama at Birmingham, […]
December 15, 2018

A probiotic-based regenerative therapy for reversing diabetes:  Probiotic VSL#3-based regenerative therapy for reversing diabetes: Probiotic VSL#3 increases the expression of Sox17, Sox2, Pdx-1, and Ngn3, decreases mTOR expression, promotes regeneration of insulin-producing ß cells, increases insulin secretion, promotes glucose homeostasis and reverses T1D and T2D via down-regulation of its target gene, 16/December/2018, 12.13 am

Introduction: What they say A study from the Longevity Institute, School of Gerontology, Department of Biological Sciences, University of Southern California, 3715 McClintock Avenue, Los Angeles, […]
December 14, 2018

Erythropoietin(EPO)/Hematopoietin-based therapy for Diabetes Mellitus: Erythropoietin(EPO) augments the expression of FGF19 and FGF1,  attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIDM, via upregulation of its target gene, 15/December/2018, 12.18 am

Introduction: What they say  A study from Diabetes and Obesity Center of Excellence, Department of Medicine, University of Washington, Seattle, Washington, USA shows that Central injection […]